 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
12 News |  |
- || betifisolimab (MSB2311) / Transcenta
Trial completion, Enrollment change, Metastases: MSB2311-CSP-002t: A Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2023
P1, N=42, Completed, Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
Recruiting --> Completed | N=60 --> 42
- || betifisolimab (MSB2311) / Transcenta
Enrollment change, Metastases: A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Dec 18, 2023
P1, N=42, Completed, Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
Recruiting --> Completed | N=60 --> 42 N=19 --> 42
- || betifisolimab (MSB2311) / Transcenta
P1 data, Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, Metastases: Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma. (Pubmed Central) - Oct 23, 2023
One partial response was also observed among 6 patients with lymphoma. MSB2311 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors and lymphomas.
- MSB2311 / Transcenta
[VIRTUAL] Updated safety and efficacy of MSB2311 (an anti-programmed death-ligand 1 antibody) in Chinese patients with advanced solid tumors and hematological malignancies from a phase 1 study. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3943;
P1
MSB2311 demonstrated a manageable safety profile and promising antitumor activity in patients with advanced solid tumors and lymphomas. MSB2311 demonstrated a manageable safety profile and promising preliminary antitumor activity in patients with advanced solid tumors and selected lymphomas.
- || betifisolimab (MSB2311) / Transcenta
Trial completion, Metastases: A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Mar 1, 2021
P1, N=19, Completed, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
MSB2311 demonstrated a manageable safety profile and promising preliminary antitumor activity in patients with advanced solid tumors and selected lymphomas. Recruiting --> Completed
- || betifisolimab (MSB2311) / Transcenta
Trial completion date, Trial primary completion date, Metastases: MSB2311-CSP-002t: A Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Mar 1, 2021
P1, N=60, Recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
Recruiting --> Completed Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- MSB2311 / Transcenta
[VIRTUAL] MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. () - Apr 29, 2020 - Abstract #ASCO2020ASCO_3386;
MSB2311 demonstrated a manageable safety profile and promising preliminary antitumor activity in patients with advanced solid tumors and hematological malignancies. Research Funding: MabSpace
- ||| betifisolimab (MSB2311) / Transcenta
New P1 trial, Metastases: MSB2311-CSP-002t: A Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Feb 16, 2020
P1, N=60, Recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
- | betifisolimab (MSB2311) / Transcenta
Trial primary completion date, PD(L)-1 Biomarker, Metastases: A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - May 14, 2019
P1, N=25, Recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
Research Funding: MabSpace Trial primary completion date: Apr 2019 --> Apr 2020
- | betifisolimab (MSB2311) / Transcenta
Enrollment open, PD(L)-1 Biomarker, Metastases: A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Apr 18, 2018
P1, N=25, Recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
Trial primary completion date: Apr 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- | betifisolimab (MSB2311) / Transcenta
New P1 trial, PD(L)-1 Biomarker, Metastases: A Phase I Study of MSB2311 in Advanced Solid Tumors (clinicaltrials.gov) - Mar 12, 2018
P1, N=25, Not yet recruiting, Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.